Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...

Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent ...

Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking ...

Discover how Temple Lung Center’s innovative clinical trials provide early access to breakthrough treatments and enhanced ...

ATXA Therapeutics, a Dublin-based pharmaceuticals business, expects to start the first trials with patients of its lung and ...

Access to a webcast of the presentation will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will provide an ...